The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/1210543.pdf
Reference44 articles.
1. Barros JC, Marshall CJ . (2005). Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 118: 1663–1671.
2. Boureux A, Furstoss O, Simon V, Roche S . (2005). c-Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and c-myc expression induced by growth factors. J Cell Sci 118: 3717–3726.
3. Bromann PA, Korkaya H, Courtneidge SA . (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957–7968.
4. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE . (1998). Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18: 2553–2558.
5. Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A . (2005). Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 6: 63–69.
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-04-18
2. Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer;Cancers;2022-06-16
3. Targeting key transcriptional factor STAT3 in colorectal cancer;Molecular and Cellular Biochemistry;2021-04-18
4. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma;Journal of Dermatological Science;2021-03
5. Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination;Toxicology and Applied Pharmacology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3